Decibel Therapeutics Added to Russell 2000 Index

Rhea-AI Summary

Decibel Therapeutics (Nasdaq: DBTX) has been added to the Russell 2000 Index as part of its quarterly IPO additions, enhancing its visibility among institutional investors. The Russell indexes, which benchmark approximately $9 trillion in assets, are crucial for investment strategies. This inclusion may positively impact Decibel's stock performance by increasing interest and liquidity. The company focuses on developing gene therapies for hearing and balance disorders, addressing significant unmet medical needs.

Positive

• Inclusion in the Russell 2000 Index may increase visibility and attract institutional investment.
• Potential for enhanced stock liquidity following index addition.

Negative

• None.

BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it has been added to the Russell 2000^® Index, as part of the index’s quarterly initial public offering (“IPO”) additions.

Russell’s U.S. indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

For more information about the Russell U.S. Indexes and the Russell Indexes reconstitution, visit the FTSE Russell website.

About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.

Investor Contact:
Julie Seidel
Managing Director
Stern Investor Relations
julie.seidel@sternir.com

Media Contact:
Stephanie Simon
Managing Director
Ten Bridge Communications
stephanie@tenbridgecommunications.com

FAQ

What is the significance of Decibel Therapeutics being added to the Russell 2000 Index?

Being added to the Russell 2000 Index enhances Decibel Therapeutics' visibility among institutional investors, which could lead to increased interest and liquidity in its stock.

How much assets are benchmarked against the Russell U.S. indexes?

Approximately $9 trillion in assets are benchmarked against the Russell U.S. indexes.

What is the primary focus of Decibel Therapeutics?

Decibel Therapeutics is dedicated to discovering and developing treatments to restore and improve hearing and balance.

What does the inclusion in the Russell 2000 Index mean for investors in DBTX?

The inclusion may increase investor interest and potentially improve the trading volume and liquidity of DBTX shares.